DE69627994D1 - Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren - Google Patents

Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren

Info

Publication number
DE69627994D1
DE69627994D1 DE69627994T DE69627994T DE69627994D1 DE 69627994 D1 DE69627994 D1 DE 69627994D1 DE 69627994 T DE69627994 T DE 69627994T DE 69627994 T DE69627994 T DE 69627994T DE 69627994 D1 DE69627994 D1 DE 69627994D1
Authority
DE
Germany
Prior art keywords
cryptosporidiosis
lactobacillus reuteri
mammals
inhibit
cryptosporidium parvum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69627994T
Other languages
English (en)
Inventor
Allen Garleb
Allen Wolf
A Casas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Original Assignee
Biogaia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB filed Critical Biogaia AB
Application granted granted Critical
Publication of DE69627994D1 publication Critical patent/DE69627994D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69627994T 1995-12-21 1996-12-20 Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren Expired - Lifetime DE69627994D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57627495A 1995-12-21 1995-12-21
PCT/US1996/020348 WO1997022353A1 (en) 1995-12-21 1996-12-20 Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals

Publications (1)

Publication Number Publication Date
DE69627994D1 true DE69627994D1 (de) 2003-06-12

Family

ID=24303696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627994T Expired - Lifetime DE69627994D1 (de) 1995-12-21 1996-12-20 Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren

Country Status (9)

Country Link
US (1) US6103227A (de)
EP (1) EP0814822B1 (de)
AT (1) ATE239486T1 (de)
AU (1) AU718040B2 (de)
CA (1) CA2213434C (de)
DE (1) DE69627994D1 (de)
ES (1) ES2199305T3 (de)
NZ (1) NZ325131A (de)
WO (1) WO1997022353A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US20050123583A1 (en) * 2000-12-18 2005-06-09 Hsing-Wen Sung Medical use of reuterin
ES2329020T3 (es) * 2002-10-18 2009-11-20 Biogaia Ab Procedimiento para potenciar la funcion inmunitaria en mamiferos usando cepas de lactobacillus reuteri.
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US7517681B2 (en) * 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
WO2005000034A2 (en) * 2003-06-23 2005-01-06 Agtech Products, Inc. Lactic bacteria and its use in direct-fed microbials
US20060078546A1 (en) * 2004-10-07 2006-04-13 Anders Zachrisson Use of lactic acid bacteria to reduce sick time
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
FI121952B (fi) 2009-05-06 2011-06-30 Oriola Oy Menetelmä pisaroina annosteltavan terveystuotteen valmistamiseksi
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
RU2721565C2 (ru) * 2014-05-05 2020-05-20 Джованни МОНЬЯ Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции
CN111789871A (zh) * 2014-05-05 2020-10-20 G·莫格纳 含罗伊氏乳杆菌ler03的组合物制备抗病毒和/或抗细菌剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
US5800813A (en) * 1996-11-12 1998-09-01 Biogaia Biologics Ab Treatment of cryptosporidium infections

Also Published As

Publication number Publication date
WO1997022353A1 (en) 1997-06-26
US6103227A (en) 2000-08-15
ATE239486T1 (de) 2003-05-15
EP0814822B1 (de) 2003-05-07
ES2199305T3 (es) 2004-02-16
CA2213434A1 (en) 1997-06-26
NZ325131A (en) 2000-08-25
EP0814822A1 (de) 1998-01-07
CA2213434C (en) 2008-12-09
AU718040B2 (en) 2000-04-06
AU1295897A (en) 1997-07-14

Similar Documents

Publication Publication Date Title
ATE239486T1 (de) Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren
Knauth The design of shift systems
HUP9901250A2 (hu) Elválasztó eszközzel ellátott abszorbens cikkek
ES2089398T3 (es) Probiotico.
ES2110027T3 (es) Fibra inorganica.
ATE124908T1 (de) Elastomere verbundstoffe mit mikrotexturierten oberflächenschichten.
ES2091918T3 (es) Estratificados elasticos modificados en el espacio.
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
OLSEN et al. Initiation and aggravation of denture stomatitis by sucrose rinses
IT1224733B (it) Trattamento batterico di conservazione della qualita' del fieno tramite aggiunta di microorganismi del genere bacillus
NO883614L (no) Molekylaer kloning og ekspresjon av humant il-3.
Aoki et al. Increased response of blood pressure to rest and handgrip in subjects with essential hypertension
ATE333281T1 (de) Agonisten und antagonisten von benzodiazepinrezeptoren des peripheren typs
DK0795130T3 (da) Diagnostisk metode ved inflammatoriske tilstande i tarmene
DE68914201D1 (de) Diagnose und Behandlung chronischer Ermüdungserscheinungen.
Altman Diurnal activity rhythm of rats with lesions of superior colliculus and visual cortex
Suave Jr The role of a colonic motility disturbance in ulcerative colitis
FR2684552B1 (fr) Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
de Visser et al. Amyotrophy of the hands and pyramidal features of predominantly the legs segregating within one large family
ATE233570T1 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
De Negri et al. Electrical status epilepticus in childhood: treatment with short cycles of high dosage benzodiazepine (preliminary note)
KITADA et al. The Problems in Controlling Heart Disease among Elementary, Junior and Senior High School Students: An Analysis of Fatal Cases: THE 7th CONFERENCE ON PREVENTION FOR RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE
Bruce Ventricular tachycardia following exercise in a case of angina pectoris
TR199801799T2 (xx) A��r� sald�rganl�k tedavisi.
Yang et al. Resting behavior of a baiji Lipotes vexillifer in captivity

Legal Events

Date Code Title Description
8332 No legal effect for de